Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orencia in Myasthenia Gravis
NCT03059888Phase 1Terminated
- Sponsor
- Johns Hopkins University
- Start
- Apr 2017
- Primary completion
- Jul 2019
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abatacept in myasthenia gravis (MG), sponsored by Johns Hopkins University. Primary endpoints: Subjective Composite Score of Myasthenia Gravis Severity at 12 months, Objective Composite Score of Myasthenia Gravis Severity at 12 months and 1 more. Started Apr 2017; status: terminated.
02
Drugs
abatacept
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT03059888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03059888.